Mackenzie Financial Corp Agenus Inc Transaction History

Mackenzie Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 25, 2023	SELL	$1.12 - $1.88 $23,466 - $39,389	-20,952 Reduced 54.24%	17,678 $19,000
Q2 2023 Aug 03, 2023	BUY	$1.31 - $2.04 $20,629 - $32,125	15,748 Added 68.82%	38,630 $61,000
Q1 2023 Apr 24, 2023	BUY	$1.45 - $2.95 $7,545 - $15,351	5,204 Added 29.44%	22,882 $34,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $3.25 $25,449 - $40,946	-12,599 Reduced 41.61%	17,678 $42,000
Q3 2022 Oct 07, 2022	SELL	$1.96 - $3.14 $3,461 - $5,545	-1,766 Reduced 5.51%	30,277 $62,000
Q2 2022 Aug 10, 2022	SELL	$1.3 - $2.64 $3,790 - $7,698	-2,916 Reduced 8.34%	32,043 $62,000
Q1 2022 May 13, 2022	BUY	$2.35 - $3.47 $8,133 - $12,009	3,461 Added 10.99%	34,959 $86,000
Q4 2021 Feb 14, 2022	BUY	$2.92 - $5.74 $20,226 - $39,760	6,927 Added 28.19%	31,498 $101,000
Q3 2021 Nov 08, 2021	BUY	$4.98 - $6.63 $71,642 - $95,379	14,386 Added 141.25%	24,571 $129,000
Q2 2021 Aug 11, 2021	BUY	$2.56 - $5.49 $26,073 - $55,915	10,185 New	10,185 $56,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.